Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01646814 · ClinicalTrials.gov registry record · Phase 2
Evaluation of Upper GI Ulceration Induced by PL2200 Versus Aspirin in At-Risk Subjects
A Phase 2 study of Gastroduodenal Ulceration, sponsored by PLx Pharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 247
- Enrollment target
- 10
- Study locations
NCT01646814 is a Phase 2 study of Gastroduodenal Ulceration that has completed, run by PLx Pharma. The registered enrollment target is 247 participants. The trial reports 10 study locations across 6 states.
The verdict
NCT01646814, a Phase 2 study of Gastroduodenal Ulceration, has completed, sponsored by PLx Pharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 247 participants
- Enrollment target
- 10
- Study locations
Study Summary
This trial is a Phase 2, randomized, controlled study to compare the degree of mucosal injury after the oral administration of an investigational product, PL2200, and a marketed 325 mg immediate-release aspirin product.
Conditions Studied
Interventions
- DRUG PL2200
- DRUG Aspirin tablets
Study Locations (10)
Texas
- - Dallas
- - Houston
- - San Antonio
Florida
- - Jupiter
- - South Miami
North Carolina
- - High Point
- - Raleigh
Maryland
- - Towson
New York
- - New York
Virginia
- - Chesapeake
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 247 participants |
| Start Date | 2012-09 |
| Est. Completion | 2013-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01646814
The ClinicalTrials.gov registry entry for NCT01646814 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 247 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is PLx Pharma, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Gastroduodenal Ulceration appearing as the primary indexed condition, and to 2 interventions - of which PL2200 is the first listed.
NCT01646814 reports 10 study locations spanning 6 distinct geographic areas - top geographies include Texas, Florida, North Carolina.
Frequently Asked Questions
What is clinical trial NCT01646814 about?
NCT01646814 is a clinical study titled "Evaluation of Upper GI Ulceration Induced by PL2200 Versus Aspirin in At-Risk Subjects". This trial is a Phase 2, randomized, controlled study to compare the degree of mucosal injury after the oral administration of an investigational product, PL2200, and a marketed 325 mg immediate-release aspirin product.
What is the current status of trial NCT01646814?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 247 participants. The study started on 2012-09. Estimated completion is 2013-06.
What conditions does trial NCT01646814 study?
This clinical trial studies the following conditions: Gastroduodenal Ulceration.
What interventions are being tested in trial NCT01646814?
The interventions under investigation include: PL2200 (DRUG), Aspirin tablets (DRUG).
Who is sponsoring clinical trial NCT01646814?
This trial is sponsored by PLx Pharma, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01646814 being conducted?
This trial has 10 study locations across Florida, Maryland, New York, North Carolina, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.